Vizora日本語

PeptiDreamPeptiDream Inc.4587東証プライム医薬品FY ending Dec 2024, consolidated, IFRS

PeptiDream FY ending Dec 2020 results

PeptiDream brought in ¥11.7B in revenue.

Out of every ¥100 of sales, about ¥60 is left as operating profit.

Revenue changed +1025.7% from the prior year, and it swung back to an operating profit.

What changed from last year

FY ending Dec 2019 → FY ending Dec 2020

Revenue
+1025.7%¥1.04B → ¥11.7B
Gross profit
+2503.8%¥366M → ¥9.53B
Operating income
Back to profit-¥887.2M → ¥6.99B
Operating cash flow
+616.1%¥242M → ¥1.73B
Free cash flow
+1005.2%¥103.7M → ¥1.15B

Where the money goes

FY ending Dec 2019 → FY ending Dec 2020

Where ¥100 of sales goes

For every ¥100 PeptiDream sells, how much goes where, and how much is kept.

FY ending Dec 2020
Cost of sales
¥18
SG&A
¥22
Operating profit
¥60
Net profit kept
¥38

Annual margin trends

Gross margin81.6%
FY ending Dec 2019: 35.3%35.3%FY ending Dec 2020: 81.6%81.6%FY19FY20
Operating margin59.9%
FY ending Dec 2019: -85.5%-85.5%FY ending Dec 2020: 59.9%59.9%FY19FY20
Net margin38.1%
FY ending Dec 2019: -47.1%-47.1%FY ending Dec 2020: 38.1%38.1%FY19FY20

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (2)

  • EDINET (FSA Japan)

    有価証券報告書－第16期(令和3年1月1日－令和3年12月31日)

    ID S100NQLE2022-03-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第15期(令和2年1月1日－令和2年12月31日)

    ID S100L1B02021-03-26Open

Extracted from XBRL: 43 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image